ChartRow logo
Data provided bySource: Twelve Data
ICLR
$195.02+1.89%
as of close, Nov 17, 2026
☾ AH $195.02 +1.89%
ICON plcStock · HealthcareNasdaq Composite · 0.03% of ONEQ
PeersCRLRVTYMEDPIQVGHLH
Share this page

ICLR — ICON plc price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in ICLR be worth today? →
ICLR returns: By year · By month · By week · Trailing

Price data

Price
$195.02
YTD price return
+7.02%
YTD total return
+7.02%
Market cap
14.9B
Enterprise value
17.8B
Shares outstanding
76.6M
52W low
$66.57
52W high
$219.04
From 52W high
-10.97%
From 52W low
+192.95%
52W range
84%$66.57–$219
Beta
1.19

Volume

Rel volume
0.60×
30D volume
1.1M
30D $ vol
213.2M

Insider trading

Insider net 1W
−$2.0M
Insider net 1M
−$4.2M
Insider net 3M
−$6.5M
Insider net 1Y
−$8.2M

Form 4 transactions by trade date, as filed; latest on file 2026-11-12.

Fundamentals

Sales (ttm)
8.3B
Sales/share
$107.77
EPS (ttm)
$2.90
FCF (ttm)
862M
FCF/share
$11.26
Book value/share
$120.07
Net margin
2.78%
ROE
2.49%
ROA
1.41%
Debt / equity
0.31×
Current ratio
1.10

Growth (CAGR, ttm) · 10Y

Sales
+0.76%+2.15%+24.16%+18.01%
Net income
-69.00%-23.15%-7.15%-0.43%
FCF
-22.95%+26.96%+10.34%+14.15%
Shares
-5.19%-2.15%+7.72%+3.37%

Per-share growth (CAGR, ttm) · 10Y

EPS
-67.44%-22.08%-13.96%-3.09%
Sales/share
+6.28%+4.39%+15.26%+14.16%
FCF/share
-18.73%+29.75%+2.43%+10.43%
Book value/share
+2.70%+4.91%+27.93%+24.07%
Price
+24.64%-10.27%-7.07%+9.73%
Total return
+24.64%-10.27%-7.07%+9.73%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
67.2×
P/OI (ttm)
33.7×
Fwd P/E
16.8×
P/S (ttm)
1.8×
P/B (mrq)
1.6×
P/FCF (ttm)
17.3×
EV/EBITDA (fy)
21.6×
EV/Sales (ttm)
2.2×
FCF yield (ttm)
5.77%
Buyback yield (realized, 1y)
5.19%
Shareholder yield (realized, 1y)
5.19%
Buyback yield (cash, ttm)
5.02%
Shareholder yield (cash, ttm)
5.02%

Vs own 10Y history

P/E
89th
P/OI
86th
P/S
15th
P/B
17th
P/FCF
20th

Bar = where today’s multiple sits in ICLR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+1.89%
5D
-4.70%
1M
+14.60%
3M
+15.09%
YTD
+7.02%
1Y
+24.62%
5Y
-30.70%
1D
+1.89%
5D
-4.70%
1M
+14.60%
3M
+15.09%
YTD
+7.02%
1Y
+24.62%
5Y
-30.70%

Fundamentals#

Revenue

5Y CAGR +24.2%10Y CAGR +18.0%
$8.3B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y CAGR +2.5%10Y CAGR +4.6%
$442.8M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

5Y CAGR −14.0%10Y CAGR −3.1%
$2.90 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y CAGR +10.3%10Y CAGR +14.2%
$862M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $1B, capex −$174.2M

No quarters filed for this figure.

Shares (diluted)

5Y +48.2%10Y +31.0%
79M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Net income

5Y CAGR −7.2%10Y CAGR −0.4%
$229.3M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full ICLR financials →

ICON plc is a clinical research organisation that provides outsourced drug and device development services to pharmaceutical, biotechnology, medical device, and public health customers. The company supports clinical development across the full product lifecycle, including study design, trial management, data solutions, site and patient access, laboratory services, and commercialization support. ICON plc also offers consulting and advisory capabilities, decentralized and hybrid trial services, real-world intelligence, and therapeutic expertise across areas such as oncology, cardiology, infectious disease, immunology, and central nervous system disorders. Its work is used to help clients run clinical programs more efficiently and bring medical treatments through development and approval pathways. Headquartered in Dublin, Ireland, ICON plc operates through a broad international network and serves organizations in multiple global markets.

Dublin, Ireland·40,200 employees·Diagnostics & Research·iconplc.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding ICLR#

3 of the 193 ETFs ChartRow carries live hold ICLR. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jul 26 to Aug 26).

FundNameFiled weight
ONEQFidelity Nasdaq Composite Index ETF0.0%
ESGVVanguard ESG U.S. Stock ETF0.0%
VTVanguard Total World Stock ETF0.0%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%